{"title": "Review on acceptability and WTP for HIV vaccine", "author": "Jppres", "url": "https://jppres.com/jppres/tag/immunization/", "hostname": "jppres.com", "description": null, "sitename": "Journal of Pharmacy & Pharmacognosy Research", "date": "2022-07-06", "cleaned_text": "J. Pharm. Pharmacogn. Res., vol. 10, no. 4, pp. 748-767, July-August 2022. DOI: [https://doi.org/10.56499/jppres22.1404_10.4.748](https://doi.org/10.56499/jppres22.1404_10.4.748) Review Acceptability of and pay for human immunodeficiency virus vaccination: A systematic literature review [Aceptabilidad y disposici\u00f3n a pagar por la vacunaci\u00f3n contra el virus de la inmunodeficiencia humana: Una revisi\u00f3n sistem\u00e1tica de virus (HIV) have considerably improved public health in the that measurements of vaccine preference, as reflected the willingness (WTP), policymakers establish health capital priorities. Aims: acceptability and Methods: A databases to identify eligible articles published from 2005 to 2020, and key terms were used in accordance with the guidelines of the via Excel. of eligible studies, 28 and 3 reported on the and systematic summary of these matters along with useful information for policymakers on maximizing public vacunas contra el virus de la inmunodeficiencia humana (VIH) han mejorado considerablemente la salud p\u00fablica en el \u00faltimo siglo. Las consideraciones importantes, sin embargo, son que la vacunaci\u00f3n efectiva depende sustancialmente de la aceptabilidad de las vacunas futuras y que las mediciones monetarias de la preferencia por la vacuna, reflejadas en la disposici\u00f3n a pagar (WTP), pueden ayudar a los formuladores de pol\u00edticas a establecer prioridades de capital de salud. Objetivos: Agrupar sistem\u00e1ticamente los datos sobre la aceptabilidad de las vacunas y la disposici\u00f3n a pagar. M\u00e9todos: Se realiz\u00f3 una b\u00fasqueda sistem\u00e1tica en cinco bases de datos para identificar art\u00edculos elegibles publicados entre 2005 y 2020, y se utilizaron t\u00e9rminos clave de acuerdo con las pautas de Preferred Reporting Items for Systematic Review and Meta-Analyses. Dos investigadores evaluaron de forma independiente los art\u00edculos, extrajeron datos relevantes y elaboraron res\u00famenes num\u00e9ricos y descriptivos para la presentaci\u00f3n de resultados a trav\u00e9s de Excel. Resultados: De los 31 estudios elegibles, 28 y 3 informaron sobre la aceptabilidad y la disposici\u00f3n a pagar por la vacunaci\u00f3n contra el VIH, respectivamente. Los niveles de aceptabilidad oscilaron entre 2,94 % y 93,10 %, con un promedio de 60,16 %, y los valores de disposici\u00f3n a pagar estuvieron entre US$ 108 y US$ 671. Los temas m\u00e1s predominantes fueron las caracter\u00edsticas de las vacunas contra el VIH (seguridad/efectos secundarios, eficacia, duraci\u00f3n de la protecci\u00f3n, seropositividad inducida por la vacuna). Conclusiones: En general, la revisi\u00f3n descubri\u00f3 la falta de escalas estandarizadas, universales y aceptables para determinar la aceptabilidad y la disposici\u00f3n a pagar. La evaluaci\u00f3n brind\u00f3 un resumen completo y sistem\u00e1tico de estos asuntos junto con informaci\u00f3n \u00fatil para los formuladores de pol\u00edticas sobre c\u00f3mo maximizar la salud p\u00fablica con recursos limitados. Palabras Clave: aceptabilidad; inmunizaci\u00f3n; revisi\u00f3n S, Anuratpanich L Acceptability of and willingness to pay for human immunodeficiency virus vaccination: A M, M, Rubincam C, Brown B, Bekker LG (2018) Contexts of vulnerability and the acceptability of new biomedical HIV technologies key D, M, Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania-the phase I/II HIVIS 03 trial. C, Moreno L, Kerrigan D (2007) Local understanding of an HIV vaccine and its relationship with HIV-related in the Dominican Moreno L, Kerrigan D (2008) Perceived influence of an HIV vaccine on sexualrisk behaviour in the Dominican Republic. Cult Health Sex University Press. Cameron MP, Newman PA, Roungprakhon S, Scarpa R (2013) The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 31: 3712-3717. Cook J, Jeuland M, Maskery B, Lauria D, Sur D, Clemens J, Bryant Frew Correlates of negative intent to receive S, G (2011) Motivators of enrolment in HIV vaccine trials: A review P, M (2019) Patients' high acceptability of a future therapeutic HIV vaccine in A French paradox? BMC Infect 19: Gichuhi M, Gakii G, Du Plessis E, health care programmes, 4th edn. Oxford, UK: Oxford University Press. Frew PM, Crosby RA, Salazar LF, Gallinot LP, Bryant LO, Holtgrave DR (2008) Acceptance of a potential HIV/AIDS women. J Med Hom Johnson Louglin A, M, R, Ellner J (1997) HIV-1 risk and (2008) Differences in HIV vaccine acceptability between genders. Breaking the silence: What homeless 18-to 24-year-olds say about HIV 18: S, K, Zimet G, Rich J (2006) Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 43: 402-405. Lee SJ, Brooks RA, Newman PA, Seiden D, Sangthong R, Duan N (2008) HIV vaccine acceptability among immigrant Thai residents Los Angeles: a mixed-method AIDS Care 20: 1161-1168. Lee SJ, Newman PA, Duan N, Cunningham WE (2014) Development of an HIV vaccine attitudes scale to predict HIV Vaccine 32: 5013-5018. Lee S, Newman P, Comulada W, Cunningham W, Duan N (2012) Use of conjoint analysis to assess HIV vaccine acceptability: Feasibility of an innovation in 76-81. Lindegger Quayle experiences of vaccination: Implications for HIV-preventive Duan N, Lee SJ, Rudy ET, Seiden DS, Kakinami L, Cunningham WE (2006) HIV vaccine acceptability among communities risk: The impact of 24: 2094-2101. Newman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, Kakinami L, Shoptaw S, Diamant A, Cunningham WE (2009) Preventive HIV vaccine acceptability and behavioral risk compensation among a sample VOICES). Health Serv Res 44: 2167-2179. Newman PA, Logie C review and behavioral risk compensation among high-risk men who have with men and transgenders in Thailand. Vaccine 28: 958-964. Newman (2012b) A of Balan IC, Mulrow Shamseer L, Tetzlaff JM, T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The Haddad L, Mulligan Anticipated Am J Health Behav 33: 391-399. Roberts KJ, Newman PA, Duan N, Rudy ET (2005) HIV vaccine and 1662. Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS (2005) HIV acceptability among women at (2005) Issues related to gay and bisexual men's acceptance 16: 546-548. Sayles JN, Macphail CL, Newman PA, WE (2010) Future HIV vaccine acceptability among young adults in a Preventive HIV Vaccine: A Review of the Literature. International AIDS Vaccine Initiative. Policy Research Working Paper # 3; pp. 39. Thabethe S, Slack C, Lindegger G, Wilkinson A, Wassenaar D, Kerr P, Bekker LG, Mngadi K, Newman PA (2018) \"Why don't you go into suburbs? Why are you targeting us?\": Trust and mistrust in HIV vaccine trials in South Africa. J Empir Res Hum Res Curr J, PA, Williams CC, Massaquoi N, Brown M (2013) \"Sisters, Mothers, Daughters and Aunties\": HIV vaccine acceptability among African, Caribbean and other Black women in Toronto. Can J Public Health 104: e413-e417. Whittington D, Suraratdecha C, Poulos users in 14: 537. Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, RM (2005) Predictors of STI acceptability "}